Literature DB >> 15322834

Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution.

D Wittke1, D Hartmann, V Gieselmann, R Lüllmann-Rauch.   

Abstract

Inherited deficiency for the lysosomal enzyme arylsulfatase A (ASA) leads to lysosomal storage of sulfatides and to dramatic demyelination in the CNS of humans (metachromatic leukodystrophy, MLD). As an animal model, ASA(-/-) mice have previously been generated by disruption of the ASA gene and are known to develop lysosomal sulfatide storage similar to that in human MLD, and, moreover, to become deaf because of degeneration of the primary neurons of the auditory pathway. The present study deals with the cellular and topographic distribution of sulfatide storage throughout the CNS of ASA(-/-) mice between a few days and 24 months of age. Sulfatide accumulation was detected on the ultrastructural level and by histochemical staining with alcian blue. Sulfatide storage was found in oligodendroglia and neurons in young mice, and in activated microglia (phagocytes) in adult mice. Neuronal sulfatide storage was most prominent in many nuclei of the medulla oblongata and pons, and in several nuclei of midbrain and forebrain. Sulfatide-storing phagocytes were most frequent in the white matter tracts of aged ASA(-/-) mice, whereas no widespread demyelination was obvious. Loss of neurons was found in two nuclei of the auditory pathway of aged ASA(-/-) mice (ventral cochlear nucleus and nucleus of trapezoid body). The distributional pattern of sulfatide storage throughout the CNS of ASA(-/-) mice largely corresponds to data reported for human MLD. An important difference, however, which remains unexplained at present, is the absence of obvious demyelination from the CNS of ASA(-/-) mice up to the age of 2 years.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322834     DOI: 10.1007/s00401-004-0883-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  27 in total

1.  Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice.

Authors:  Françoise Piguet; Dolan Sondhi; Monique Piraud; Françoise Fouquet; Neil R Hackett; Ornella Ahouansou; Marie-Thérèse Vanier; Ivan Bieche; Patrick Aubourg; Ronald G Crystal; Nathalie Cartier; Caroline Sevin
Journal:  Hum Gene Ther       Date:  2012-07-23       Impact factor: 5.695

2.  Toward a better understanding of brain lesions during metachromatic leukodystrophy evolution.

Authors:  A Martin; C Sevin; C Lazarus; C Bellesme; P Aubourg; C Adamsbaum
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

Review 3.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

4.  Quantification of sulfatides and lysosulfatides in tissues and body fluids by liquid chromatography-tandem mass spectrometry.

Authors:  Mina Mirzaian; Gertjan Kramer; Ben J H M Poorthuis
Journal:  J Lipid Res       Date:  2015-01-27       Impact factor: 5.922

5.  Sulfatides Primarily Exist in the Substantia Nigra Region of Mouse Brain Tissue.

Authors:  Kab-Tae Park; Jong Cheol Shon; Ji-Eun Kim; Gyu Hwan Park; Hyun Jin Choi; Kwang-Hyeon Liu
Journal:  Lipids       Date:  2017-01-11       Impact factor: 1.880

6.  Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates.

Authors:  Jonathan B Rosenberg; Dolan Sondhi; David G Rubin; Sébastien Monette; Alvin Chen; Sara Cram; Bishnu P De; Stephen M Kaminsky; Caroline Sevin; Patrick Aubourg; Ronald G Crystal
Journal:  Hum Gene Ther Clin Dev       Date:  2014-08-21       Impact factor: 5.032

7.  Anti-inflammatory Therapy With Simvastatin Improves Neuroinflammation and CNS Function in a Mouse Model of Metachromatic Leukodystrophy.

Authors:  Axel Stein; Stijn Stroobants; Volkmar Gieselmann; Rudi D'Hooge; Ulrich Matzner
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

8.  Successful treatment of metachromatic leukodystrophy using bone marrow transplantation of HoxB4 overexpressing cells.

Authors:  Noriko Miyake; Koichi Miyake; Stefan Karlsson; Takashi Shimada
Journal:  Mol Ther       Date:  2010-04-27       Impact factor: 11.454

Review 9.  Pathology and current treatment of neurodegenerative sphingolipidoses.

Authors:  Matthias Eckhardt
Journal:  Neuromolecular Med       Date:  2010-08-22       Impact factor: 3.843

10.  Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.

Authors:  Ulrich Matzner; Renate Lüllmann-Rauch; Stijn Stroobants; Claes Andersson; Cecilia Weigelt; Carl Eistrup; Jens Fogh; Rudi D'Hooge; Volkmar Gieselmann
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.